Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial - Takeaways - MDSpire

Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial

  • By

  • Xiangjin Gao

  • Ruiqi Cai

  • Jinrong Lu

  • Zhen Duan

  • Quanruo Xu

  • Xiuqi Zhang

  • Fanlingzi Shen

  • Rui Zhang

  • Bin Li

  • Ruiping Wang

  • May 21, 2026

  • 0 min

Share

  • 1

    A randomized, double-blind, placebo-controlled trial will assess the efficacy and safety of MuShengshu for mild-to-moderate atopic dermatitis.

  • 2

    The study will enroll 66 patients, with a treatment group receiving MuShengshu and a control group receiving a placebo.

  • 3

    Primary outcome will be the proportion of patients achieving ≥50% improvement in the Eczema Area and Severity Index at week 4.

  • 4

    Secondary outcomes include assessments of EASI, Visual Analogue Scale, Investigator’s Global Assessment, and Dermatology Life Quality Index.

  • 5

    The trial aims to provide evidence for incorporating traditional Chinese herbal bath solutions into atopic dermatitis management.

Original Source(s)

Efficacy and safety of MuShengshu in the treatment of mild-to-moderate atopic dermatitis: protocol for a randomized, double-blind, placebo-controlled trial

  • by Xiangjin Gao, Ruiqi Cai, Jinrong Lu, Zhen Duan, Quanruo Xu, Xiuqi Zhang, Fanlingzi Shen, Rui Zhang, Bin Li, Ruiping Wang

  • May 21, 2026

Related Content

Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review

DFU-GCNet: a global context-enhanced inception network for robust and interpretable diabetic foot ulcer classification

Development and preliminary clinical validation of a mobile health application for pressure injury staging in ICU patients